Abstract
The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therapeutic combinations are emerging, with companies pairing two immunotherapies, an immunotherapy and a molecularly targeted therapy, or an immunotherapy plus traditional chemotherapy in order to more effectively fight cancer. Some immunotherapies are also pairing with companion diagnostics in order to maximize efficacy in patient populations. All of these developments come with their own unique challenges that drug developers will need to confront. This Perspective article reviews developments in the IO field and highlights key challenges in successfully commercializing an IO therapy.
Keywords: Commercialization, companion diagnostics, immuno-oncology, oncology, precision medicine.
Current Pharmacogenomics and Personalized Medicine
Title:IO Nation: The Rise of Immuno-Oncology
Volume: 12 Issue: 3
Author(s): Scott Palmer, Georgiana L. Kuhlmann and Kristin Pothier
Affiliation:
Keywords: Commercialization, companion diagnostics, immuno-oncology, oncology, precision medicine.
Abstract: The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therapeutic combinations are emerging, with companies pairing two immunotherapies, an immunotherapy and a molecularly targeted therapy, or an immunotherapy plus traditional chemotherapy in order to more effectively fight cancer. Some immunotherapies are also pairing with companion diagnostics in order to maximize efficacy in patient populations. All of these developments come with their own unique challenges that drug developers will need to confront. This Perspective article reviews developments in the IO field and highlights key challenges in successfully commercializing an IO therapy.
Export Options
About this article
Cite this article as:
Palmer Scott, Kuhlmann L. Georgiana and Pothier Kristin, IO Nation: The Rise of Immuno-Oncology, Current Pharmacogenomics and Personalized Medicine 2014; 12 (3) . https://dx.doi.org/10.2174/1875692113666150115222451
DOI https://dx.doi.org/10.2174/1875692113666150115222451 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Urinary Tract Tumors, Biology and Risk for Artificial Sweeteners Use with Particular Emphasis on some South American Countries
Current Nutrition & Food Science Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors
Current Drug Targets Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Current Pharmaceutical Design Methotrexate: Should We Start Using it in Clinical Practice?
Current Drug Targets Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry Curcumin: A Boon to Colonic Diseases
Current Drug Targets Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations
Current Pharmaceutical Design Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Gamma-Amino Butyric Acid Inhibits the Nicotine-Imposed Stimulatory Challenge in Xenograft Models of Non-Small Cell Lung Carcinoma
Current Cancer Drug Targets Targets for Steroid Hormone Mediated Actions of Periodontal Pathogens, Cytokines and Therapeutic Agents Some Implications on Tissue Turnover in the Periodontium
Current Drug Targets Bridging Indigenous Knowledge and Scientific Evidence for Pharmacological Studies of <i>Phaleria macrocarpa</i>: A Systematic Review
The Natural Products Journal Evaluation of Anti-aging Compounds Using the Promoters of Elastin and Fibrillin-1 Genes Combined with a Secreted Alkaline Phosphatase Reporter in Normal Human Fibroblasts
Current Pharmaceutical Biotechnology Ultrasound Enhances the Transfection of Plasmid DNA by Non-viral Vectors
Current Pharmaceutical Biotechnology Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry NRF2-Dependent Glutamate-L-Cysteine Ligase Catalytic Subunit Expression Mediates Insulin Protection Against Hyperglycemia-Induced Brain Endothelial Cell Apoptosis
Current Neurovascular Research Transcription Factor Profiling Shows New Ways Towards New Treatment Options of Cutaneous T cell lymphomas
Current Drug Discovery Technologies RAGE and RAGE Ligands in Cancer
Current Molecular Medicine Ecosustainable Development of Novel Bio-inorganic Hybrid Materials as UV Protection Systems for Potential Cosmetic Applications
Current Pharmaceutical Biotechnology